Systematic review: Molecular chemoprevention of colorectal malignancy by mesalazine

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 2, 2010, Pages 202-209

  Lyakhovich, A ^a   Gasche, C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESALAZINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P53; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SALAZOSULFAPYRIDINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN;

ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER PREVENTION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CHEMOPROPHYLAXIS; COLORECTAL CANCER; DRUG MECHANISM; ENTERITIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW;

CELL LINE, TUMOR; CHEMOPREVENTION; COLORECTAL NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MESALAMINE; PRECANCEROUS CONDITIONS;

EID: 72949095645     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04195.x     Document Type: Review

References (80)

1. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol 1994 12 : 851 873.
2. Half E, Arber N. Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin Pharmacother 2009 10 : 211 219.
3. Andrews JM, Travis SP, Gibson PR, Gasche C. Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Aliment Pharmacol Ther 2009 29 : 459 469.
4. Brain O, Travis SP. Therapy of ulcerative colitis: state of the art. Curr Opin Gastroenterol 2008 24 : 469 474.
5. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977 2 : 892 895.
6. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998 115 : 182 205.
7. Gasche C. Review article: the chemoprevention of colorectal carcinoma. Aliment Pharmacol Ther 2004 20 (Suppl 4 31 5.
8. Stolfi C, Pellegrini R, Franze E, Pallone F, Monteleone G. Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol 2008 14 : 4434 4439.
9. Sandborn WJ. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations? J Clin Gastroenterol 2008 42 : 338 344.
10. Layer PH, Goebell H, Keller J, Dignass A, Klotz U. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology 1995 108 : 1427 1433.
11. Thorpe MP, Ehrenpreis ED, Putt KS, Hannon B. A dynamic model of colonic concentrations of delayed-release 5-aminosalicylic acid (Asacol). Aliment Pharmacol Ther 2009 29 : 1193 1201.
12. Stolfi C, Fina D, Caruso R, et al. Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol 2008 75 : 668 676.
13. Peskar BM, Dreyling KW, May B, Schaarschmidt K, Goebell H. Possible mode of action of 5-aminosalicylic acid. Dig Dis Sci 1987 32 : 51S 6S.
14. Egan LJ, Mays DC, Huntoon CJ, et al. Inhibition of interleukin-1- stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 1999 274 : 26448 26453.
15. Bos CL, Diks SH, Hardwick JC, Walburg KV, Peppelenbosch MP, Richel DJ. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis 2006 27 : 2371 2382.
16. Soderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009 136 : 1561 1567.
17. de Bruin RA, Wittenberg C. All eukaryotes: before turning off G1-S transcription, please check your DNA. Cell Cycle 2009 8 : 214 217.
18. Freemantle SJ, Liu X, Feng Q, et al. Cyclin degradation for cancer therapy and chemoprevention. J Cell Biochem 2007 102 : 869 877.
19. Luciani MG, Campregher C, Fortune JM, Kunkel TA, Gasche C. 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 2007 132 : 221 235.
20. Gasche C, Goel A, Natarajan L, Boland CR. Mesalazine improves replication fidelity in cultured colorectal cells. Cancer Res 2005 65 : 3993 3997.
21. Campregher C, Luciani MG, Biesenbach P, Evstatiev R, Lyakhovich A, Gasche C. The position of the amino group on the benzene ring is critical for mesalamine's improvement of replication fidelity. Inflamm Bowel Dis 2009 [Epub ahead of print].
22. Klanrit P, Taebunpakul P, Flinterman MB, et al. PML involvement in the p73-mediated E1A-induced suppression of EGFR and induction of apoptosis in head and neck cancers. Oncogene 2009 28 : 3499 3512.
23. Lui VW, Grandis JR. EGFR-mediated cell cycle regulation. Anticancer Res 2002 22 : 1 11.
24. Santiskulvong C, Sinnett-Smith J, Rozengurt E. EGF receptor function is required in late G(1) for cell cycle progression induced by bombesin and bradykinin. Am J Physiol Cell Physiol 2001 281 : C886 98.
25. Monteleone G, Franchi L, Fina D, et al. Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death Differ 2006 13 : 202 211.
26. Rexer BN, Engelman JA, Arteaga CL. Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 2009 8 : 18 22.
27. Fina D, Franchi L, Caruso R, et al. 5-aminosalicylic acid enhances anchorage-independent colorectal cancer cell death. Eur J Cancer 2006 42 : 2609 2616.
28. Clapper ML, Gary MA, Coudry RA, et al. 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. Inflamm Bowel Dis 2008 14 : 1341 1347.
29. Koelink PJ, Mieremet-Ooms MA, Corver WE, et al. 5-aminosalicylic acid interferes in the cell cycle of colorectal cancer cells and induces cell death modes. Inflamm Bowel Dis 2009 [Epub ahead of print].
30. Schwab M, Reynders V, Steinhilber D, Stein J. Combined treatment of Caco-2 cells with butyrate and mesalazine inhibits cell proliferation and reduces Survivin protein level. Cancer Lett 2009 273 : 98 106.
31. Herold S, Herkert B, Eilers M. Facilitating replication under stress: an oncogenic function of MYC? Nat Rev Cancer 2009 9 : 441 444.
32. Gatti G, Maresca G, Natoli M, et al. MYC prevents apoptosis and enhances endoreduplication induced by paclitaxel. PLoS ONE 2009 4 : e5442.
33. Chu EC, Chai J, Ahluwalia A, Tarnawski AS. Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action? Liment Pharmacol Ther 2007 25 : 1443 1449.
34. Dominguez-Sola D, Ying CY, Grandori C, et al. Non-transcriptional control of DNA replication by c-Myc. Nature 2007 448 : 445 451.
35. Pérez de Castro I, de Cárcer G, Montoya G, Malumbres M. Emerging cancer therapeutic opportunities by inhibiting mitotic kinases. Curr Opin Pharmacol 2008 8 : 375 383.
36. Ray D, Kiyokawa H. CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability. Cancer Res 2008 68 : 1251 1253.
37. Stolfi C, Fina D, Caruso R, et al. Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase. Carcinogenesis 2008 29 : 1258 1266.
38. Wang Z, Kar S, Carr BI. Cdc25A protein phosphatase: a therapeutic target for liver cancer therapies. Anticancer Agents Med Chem 2008 8 : 863 871.
39. Joshi R, Kumar S, Unnikrishnan M, Mukherjee T. Free radical scavenging reactions of sulfasalazine, 5-aminosalicylic acid and sulfapyridine: mechanistic aspects and antioxidant activity. Free Radic Res 2005 39 : 1163 1172.
40. Rubin DT, Cruz-Correa MR, Gasche C, et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 2008 14 : 265 274.
41. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004 126 : 451 459.
42. Lopez-Alarcon C, Rocco C, Lissi E, et al. Reaction of 5-aminosalicylic acid with peroxyl radicals: protection and recovery by ascorbic acid and amino acids. Pharm Res 2005 22 : 1642 1648.
43. Lopez-Alarcon C, Speisky H, Lissi E. Antioxidant effect of 5-amino salicylic acid on copper-mediated LDL oxidation. Biol Res 2007 40 : 155 162.
44. Ancha HR, Kurella RR, McKimmey CC, Lightfoot S, Harty RF. Luminal antioxidants enhance the effects of mesalamine in the treatment of chemically induced colitis in rats. Exp Biol Med (Maywood.) 2008 233 : 1301 1308.
45. Ancha HR, Kurella RR, McKimmey CC, Lightfoot S, Harty RF. Effects of N-acetylcysteine plus mesalamine on prostaglandin synthesis and nitric oxide generation in TNBS-induced colitis in rats. Dig Dis Sci 2009 54 : 758 766.
46. Horvath K, Varga C, Berko A, Posa A, Laszlo F, Whittle BJ. The involvement of heme oxygenase-1 activity in the therapeutic actions of 5-aminosalicylic acid in rat colitis. Eur J Pharmacol 2008 581 : 315 323.
47. Mantena SK, Unnikrishnan MK, Joshi R, Radha V, Devi PU, Mukherjee T. In vivo radioprotection by 5-aminosalicylic acid. Mutat Res 2008 650 : 63 79.
48. Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radio- resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide 2008 19 : 205 216.
49. Wink DA, Miranda KM, Espey MG, et al. Mechanisms of the antioxidant effects of nitric oxide. Antioxid Redox Signal 2001 3 : 203 213.
50. Nandi J, Saud B, Zinkievich JM, Palma DT, Levine RA. 5-aminosalicylic acid improves indomethacin-induced enteropathy by inhibiting iNOS transcription in rats. Dig Dis Sci 2008 53 : 123 132.
51. Beutler B, Cerami A. The biology of cachectin/TNF - a primary mediator of the host response. Annu Rev Immunol 1989 7 : 625 655.
52. Greten FR, Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett 2004 206 : 193 199.
53. Karin M, Gallagher E. TNFR signaling: ubiquitin-conjugated TRAFfic signals control stop-and-go for MAPK signaling complexes. Immunol Rev 2009 228 : 225 240.
54. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009 27 : 693 733.
55. Solt LA, May MJ. The IkappaB kinase complex: master regulator of NF-kappaB signaling. Immunol Res 2008 42 : 3 18.
56. van Dullemen HM, Van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995 109 : 129 135.
57. Song M, Xia B, Li J. Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1beta, and nuclear factor kappaB in trinitrobenzene sulphonic acid induced colitis in rats. Postgrad Med J 2006 82 : 130 135.
58. Joo K, Lee Y, Choi D, et al. An anti-inflammatory mechanism of taurine conjugated 5-aminosalicylic acid against experimental colitis: taurine chloramine potentiates inhibitory effect of 5-aminosalicylic acid on IL-1beta-mediated NFkappaB activation. Eur J Pharmacol 2009 618 : 91 7.
59. Kang DW, Park MH, Lee YJ, et al. Phorbol ester up-regulates phospholipase D1 but not phospholipase D2 expression through a PKC/Ras/ERK/NFkappaB-dependent pathway and enhances matrix metalloproteinase-9 secretion in colon cancer cells. J Biol Chem 2008 283 : 4094 4104.
60. Kim YH, Kim MH, Kim BJ, et al. Inhibition of cell proliferation and invasion in a human colon cancer cell line by 5-aminosalicylic acid. Dig Liver Dis 2009 41 : 328 337.
61. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006 72 : 1605 1621.
62. Romano MF. Targeting TGFbeta-mediated processes in cancer. Curr Opin Drug Discov Devel 2009 12 : 253 263.
63. Koelink PJ, Hawinkels LJ, Wiercinska E, et al. 5-Aminosalicylic acid inhibits TGF-beta1 signalling in colorectal cancer cells. Cancer Lett 2009 [Epub ahead of print].
64. Mutoh M, Niho N, Komiya M, et al. Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice. Carcinogenesis 2008 29 : 824 829.
65. Bordonaro M, Lazarova DL, Sartorelli AC. Hyperinduction of Wnt activity: a new paradigm for the treatment of colorectal cancer? Oncol Res 2008 17 : 1 9.
66. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004 303 : 1483 1487.
67. Parenti S, Ferrarini F, Zini R, et al. Mesalazine inhibits the beta-catenin signalling pathway acting through the up-regulation of mu-protocadherin gene in colo-rectal cancer cells. Aliment Pharmacol Ther 2009 [Epub ahead of print].
68. Jansson EA, Are A, Greicius G, et al. The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells. Proc Natl Acad Sci USA 2005 102 : 1460 1465.
69. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med 2005 201 : 1205 1215.
70. Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther 2006 24 (Suppl 1 2 9.
71. Das KK, Bajpai M, Kong Y, Liu J, Geng X, Das KM. Mesalamine suppresses the expression of TC22, a novel tropomyosin isoform associated with colonic neoplasia. Mol Pharmacol 2009 76 : 183 191.
72. Koelink PJ, Robanus-Maandag EC, Devilee P, Hommes DW, Lamers CB, Verspaget HW. 5-Aminosalicylic acid inhibits colitis-associated but not sporadic colorectal neoplasia in a novel conditional Apc mouse model. Carcinogenesis 2009 30 : 1217 1224.
73. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005 43 : 3380 3389.
74. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998 115 : 1405 1413.
75. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004 127 : 412 421.
76. Pineton de CG, Colombel JF, Poulain D, Darfeuille-Michaud A. Pathogenic agents in inflammatory bowel diseases. Curr Opin Gastroenterol 2008 24 : 440 447.
77. Carvalho FA, Barnich N, Sivignon A, et al. Crohn's disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J Exp Med 2009 206 : 2179 2189.
78. Swidsinski A, Khilkin M, Kerjaschki D, et al. Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology 1998 115 : 281 286.
79. Subramanian S, Rhodes JM, Hart CA, et al. Characterization of epithelial IL-8 response to inflammatory bowel disease mucosal E. coli and its inhibition by mesalamine. Inflamm Bowel Dis 2008 14 : 162 175.
80. Kaufman J, Griffiths TA, Surette MG, Ness S, Rioux KP. Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression. Inflamm Bowel Dis 2009 15 : 985 996.